Lupin Limited and Polish biopharmaceutical company Celon Pharma have announced that they will co-develop a generic version of GSK’s Advair Diskus. Celon, which currently markets a fluticasone/salmeterol DPI called Salmex in Poland, will supply the the product to Lupin, and Lupin will commercialize the product in North America and “other key markets.”
Lupin CEO Vinita Gupta commented, “This collaboration is an important milestone in Lupin’s efforts to evolve its global inhalation pipeline. We are very pleased to partner with Celon given their experience in the development and manufacturing of fluticasone/salmeterol DPI in Europe. This coupled with Lupin’s expertise in inhalation product development and commercialization in the US and other markets will accelerate the development of generic Advair Diskus for global markets. We look forward to providing access to high quality, affordable fluticasone/salmeterol DPI as part of our strategy to deliver inhaled products to key markets.”
Celon CEO and Managing Director Maciej Wieczorek said, “Our scientific and technical teams look forward to collaborating with Lupin to bring this product to major markets outside of Poland. We are enthusiastic and believe that both the companies would work together to complete a time bound research and development program to ensure successful registration in targeted markets, for Lupin to effectively commercialize the product.”
Read the Lupin and Celon press release.
